ERIS.NS Balance Sheet
Eris Lifesciences Ltd.
Profit & Loss Balance Sheet Cash Flow
Balance Sheet · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-24 01:34
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Property, Plant and Equipment | ₹3.56 Bn | ₹5.05 Bn | ₹6.62 Bn | ₹7.08 Bn | PropertyPlantAndEquipment |
| Capital Work-in-Progress | ₹0.21 Bn | ₹0.19 Bn | ₹0.67 Bn | ₹1.71 Bn | CapitalWorkInProgress |
| Goodwill | ₹3.32 Bn | ₹8.61 Bn | ₹9.12 Bn | ₹9.12 Bn | Goodwill |
| Other Intangible Assets | ₹18.80 Bn | ₹29.62 Bn | ₹37.32 Bn | ₹35.67 Bn | OtherIntangibleAssets |
| Non-current Investments | ₹0.07 Bn | ₹0.16 Bn | ₹0.11 Bn | ₹0.10 Bn | NoncurrentInvestments |
| Other Non-current Assets | ₹0.24 Bn | ₹0.67 Bn | ₹0.34 Bn | ₹1.51 Bn | OtherNoncurrentAssets |
| Total Non-current Assets | ₹29.03 Bn | ₹47.47 Bn | ₹57.71 Bn | ₹58.26 Bn | NoncurrentAssets |
| Inventories | ₹1.31 Bn | ₹1.89 Bn | ₹3.35 Bn | ₹4.37 Bn | Inventories |
| Trade Receivables | ₹2.93 Bn | ₹4.22 Bn | ₹4.59 Bn | ₹6.80 Bn | TradeReceivablesCurrent |
| Cash and Cash Equivalents | ₹0.56 Bn | ₹0.94 Bn | ₹2.00 Bn | ₹0.55 Bn | CashAndCashEquivalents |
| Current Investments | ₹0.30 Bn | ₹0.00 Bn | ₹0.05 Bn | ₹0.00 Bn | CurrentInvestments |
| Other Current Assets | ₹2.47 Bn | ₹2.83 Bn | ₹1.93 Bn | ₹2.94 Bn | OtherCurrentAssets |
| Total Current Assets | ₹7.65 Bn | ₹23.02 Bn | ₹12.63 Bn | ₹15.40 Bn | CurrentAssets |
| Total Assets | ₹36.67 Bn | ₹70.49 Bn | ₹70.33 Bn | ₹73.66 Bn | Assets |
| Equity Share Capital | ₹0.14 Bn | ₹0.14 Bn | ₹0.14 Bn | ₹0.14 Bn | EquityShareCapital |
| Other Equity | ₹21.82 Bn | ₹25.73 Bn | ₹28.41 Bn | ₹38.89 Bn | OtherEquity |
| Equity Attributable to Owners | ₹21.96 Bn | ₹25.86 Bn | ₹28.54 Bn | ₹39.03 Bn | EquityAttributableToOwnersOfParent |
| Non-controlling Interests | ₹0.25 Bn | ₹6.36 Bn | ₹4.17 Bn | ₹-0.07 Bn | NonControllingInterest |
| Total Equity | ₹22.21 Bn | ₹32.22 Bn | ₹32.72 Bn | ₹38.96 Bn | Equity |
| Long-term Borrowings | ₹6.44 Bn | ₹6.55 Bn | ₹17.82 Bn | ₹9.56 Bn | BorrowingsNoncurrent |
| Total Non-current Liabilities | ₹10.03 Bn | ₹12.95 Bn | ₹23.80 Bn | ₹13.93 Bn | NoncurrentLiabilities |
| Short-term Borrowings | ₹1.86 Bn | ₹20.81 Bn | ₹6.96 Bn | ₹13.54 Bn | BorrowingsCurrent |
| Trade Payables | ₹1.25 Bn | ₹2.68 Bn | ₹3.32 Bn | ₹3.30 Bn | TradePayablesCurrent |
| Other Current Liabilities | ₹0.22 Bn | ₹0.49 Bn | ₹0.66 Bn | ₹0.72 Bn | OtherCurrentLiabilities |
| Total Current Liabilities | ₹4.43 Bn | ₹25.32 Bn | ₹13.81 Bn | ₹20.77 Bn | CurrentLiabilities |
| Total Equity and Liabilities | ₹36.67 Bn | ₹70.49 Bn | ₹70.33 Bn | ₹73.66 Bn | EquityAndLiabilities |
Every figure above is the exact value of the named XBRL element from ERIS.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).